We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis.
- Authors
Iihara, Hirotoshi; Abe, Masakazu; Wada, Makoto; Iino, Keiko; Akechi, Tatsuo; Imamura, Chiyo K.; Okuyama, Ayako; Ozawa, Keiko; Kim, Yong-Il; Sasaki, Hidenori; Satomi, Eriko; Takeda, Masayuki; Tanaka, Ryuhei; Nakajima, Takako Eguchi; Nakamura, Naoki; Nishimura, Junichi; Noda, Mayumi; Hayashi, Kazumi; Higashi, Takahiro; Boku, Narikazu
- Abstract
Background: The Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis 2023 was extensively revised to reflect the latest advances in antineoplastic agents, antiemetics, and antineoplastic regimens. This update provides new evidence on the efficacy of antiemetic regimens. Methods: Guided by the Minds Clinical Practice Guideline Development Manual of 2017, a rigorous approach was used to update the guidelines; a thorough literature search was conducted from January 1, 1990, to December 31, 2020. Results: Comprehensive process resulted in the creation of 13 background questions (BQs), 12 clinical questions (CQs), and three future research questions (FQs). Moreover, the emetic risk classification was also updated. Conclusions: The primary goal of the present guidelines is to provide comprehensive information and facilitate informed decision-making, regarding antiemetic therapy, for both patients and healthcare providers.
- Subjects
JAPAN; MEDICAL personnel; CANCER chemotherapy; ONCOLOGY; ANTINEOPLASTIC agents; RESEARCH questions
- Publication
International Journal of Clinical Oncology, 2024, Vol 29, Issue 7, p873
- ISSN
1341-9625
- Publication type
Article
- DOI
10.1007/s10147-024-02535-x